Recent evidence has suggested that T lymphocyte activation and the recruitment and activation of eosinophils may be important in the development of airflow limitation in bronchial asthma. For example, peripheral blood CD4 T helper lymphocytes from patients with acute severe asthma expressed activation markers (interleukin-2 receptor (CD25), class II molecule (HLA DR), and the very late activation marker (VLA-1)) to a greater degree than those from controls. The degree of T lymphocyte activation was closely correlated with lung function and decreased with a time course that paralleled improvements in peak expiratory flow rates.' Electron microscopical studies of bronchial biopsy specimens from asthmatic patients demonstrated mucosal lymphocyte irregularities suggestive of activation.2 Immunohistological studies of such specimens showed increased numbers of cells in the mucosa expressing IL-2 receptor as shown by positive staining with a monoclonal antibody directed against CD25.3 Flow cytometry allows simultaneous identification of phenotypic and activation markers on cells in suspension. This has recently been applied to bronchoalveolar lavage fluid and blood cells from asthmatic patients. The results showed an increase in numbers of activated CD4 and CD8 T cells in both bronchoalveolar lavage fluid and blood from asthmatic patients compared with normal healthy non-atopic control subjects. 
Abstract
Background Bronchial mucosal inflammation and epithelial damage are characteristic features ofasthma. Activation of T helper lymphocytes may contribute to this process by mechanisms including the release of cytokines promoting eosinophil infiltration and activation. Methods Bronchial washings and bronchoalveolar lavage fluid were obtained from 29 atopic asthmatic patients (19 with current symptoms and 10 symptom free) and 13 normal volunteers. Flow cytometry was used to assess T cell phenotype and activation status in bronchoalveolar lavage fluid and peripheral blood, and differential cell counts were made on bronchial washings and bronchoalveolar lavage fluid. Findings were related to severity of disease as reflected by symptom scores, baseline lung function, and airway responsiveness. Results CD4 T lymphocytes in bronchoalveolar lavage fluid and blood from asthmatic patients were activated by comparison with controls (CD4 CD25, median 16-8% v 8-7% for bronchoalveolar lavage fluid, and 15-3% v 8-7% in blood). Bronchoalveolar lavage fluid CD4 T cells from both asthmatic patients and controls were of memory phenotype (95-8% and 96-8% CD45RO and 1-7% and 04% CD45RA respectively), whereas both CD45RO and CD45RA T cells were present in blood. Patients with asthma and current symptoms showed increased bronchoalveolar T cell activation compared with patients without symptoms (CD4 CD25 18-7% v 12-3%). Within the asthmatic group there was a significant association between CD4 CD25 lymphocytes and asthma symptom scores (r. = 075), airway methacholine responsiveness (log PC20, rs = -O043) and baseline FEV, (r5 = -039). Conclusion These results support the hypothesis that selective activation of memory CD4 T cells contributes to eosinophil accumulation, bronchial hyperresponsiveness, and symptoms in asthma. (Thorax 1993; 48:26-32) Recent evidence has suggested that T lymphocyte activation and the recruitment and activation of eosinophils may be important in the development of airflow limitation in bronchial asthma. For example, peripheral blood CD4 T helper lymphocytes from patients with acute severe asthma expressed activation markers (interleukin-2 receptor (CD25), class II molecule (HLA DR), and the very late activation marker (VLA-1)) to a greater degree than those from controls. toms and the degree of bronchial responsiveness as assessed by inhaled methacholine.
Methods

PATIENTS
Asthmatic patients (table 1) were recruited from the allergy clinic of the Royal Brompton National Heart and Lung Hospital, and normal volunteers from the staff of the National Heart and Lung Institute. All subjects gave written informed consent and the study was appoved by the ethics committee. They were all nonsmokers and none had received oral or inhaled corticosteroids in the three months preceding the study. ists more than twice a week). Ten asthmatic patients had strictly allergen related symptoms and had no symptoms when studied out of season or after allergen avoidance. To define the severity of asthma symptoms an Aas symptom score '9 was allocated on the basis of a questionnaire administered by a clinician who was not involved in the laboratory measurements (AMB). The FEV, was measured with a dry bellows spirometer (Vitalograph, Buckingham, UK). Methacholine PC2020 was measured between 0800 and 0900 at least 48 hours before bronchoscopy. Normal volunteers were without symptoms and had negative skinprick responses, low total IgE, and no detectable serum allergen specific IgE to common aeroallergens.
FIBREOPTIC BRONCHOSCOPY
All fibreoptic bronchoscopies were performed by the same operator (SRD) between 0800 and 0900. Asthmatic patients and normal subjects wre premedicated with 2 5 mg of nebulised salbutamol, intravenous atropine (0 5 mg), and midazolam as required for sedation (5-10 mg).
Topical anaesthesia was with 2% lignocaine. 
Results
Fibreoptic bronchoscopy was well tolerated by all subjects. Occasional mild bronchospasm in eight of the subjects induced by the procedure was rapidly reversed by the administration of nebulised salbutamol.
There was a small but significant reduction in the total bronchoalveolar lavage fluid recovered from asthmatic patients compared with normal subjects (median 115 ml v 130 ml, estimated median difference 20-0,95 % CI for difference -35-0 to 0-01, p < 0-05). There was no difference in total cell recovery between the two *Counts in bronchial washings from 25 asthmatic patients (four were too mucoid for analysis). Previous activation leading to memory status may explain continued expression of late activation markers; indeed the flI chain of VLA-1 (CD29) has been used as a marker of memory T cells.30 Airway T cells might be expected to encounter antigens frequently, and the transient expression of CD25, rather than the more prolonged expression of late activation markers, might more accurately reflect ongoing allergenic T cell stimulation in asthma.
It is possible that the increased level of T lymphocyte activation and eosinophilia that we found in our atopic asthmatic patients may reflect the atopic state rather than asthma itself. Further studies including a group of nonasthmatic subjects would be required to exclude this possibility. The correlation with severity of asthma shown here, however, together with findings from studies of peripheral blood' and bronchial mucosal biopsy samples from both extrinsic2 and intrinsic asthmatic patients,3' strongly supports the role of CD4 T cell activation in asthma, rather than simply the atopic state.
The Aas symptom score that we employed uses five categories of asthma based on severity and duration of attacks, resting lung function, and treatment requirements.'9 No grading system of asthma is widely accepted as satisfactory, but this system does allow stratification of patients and our findings concur with a previous report of significant correlations 
